Research Paper Volume 10, Issue 3 pp 339—357
Methylomic survival predictors, frailty, and mortality
- 1 Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg D-69120, Germany
- 2 German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg D-69120, Germany
- 3 Network Ageing Research, University of Heidelberg, Heidelberg 69115, Germany
- 4 Saarland Cancer Registry, Saarbrücken, D-66119, Germany
- 5 Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg D-69120, Germany
Received: December 27, 2017 Accepted: March 2, 2018 Published: March 6, 2018
https://doi.org/10.18632/aging.101392How to Cite
Abstract
Survival predictors are of potential use for informing on biological age and targeting prevention of aging-related morbidity. We assessed associations of 2 novel methylomic survival indicators, a methylation-based mortality risk score (MRscore) and the epigenetic clock-derived age acceleration (AA), with a well-known survival predictor, frailty index (FI), and compared the 3 indicators in mortality prediction. In a large population-based cohort with 14-year follow-up, we found both MRscore and AA to be independently associated with FI, but the association was much stronger for MRscore than for AA. Although all 3 indicators were individually associated with all-cause mortality, robust associations only persisted for MRscore and FI when simultaneously including the 3 indicators in regression models, with hazard ratios (95% CI) of 1.91 (1.63–2.22), 1.37 (1.25–1.51), and 1.05 (0.90–1.22), respectively, per standard deviation increase of MRscore, FI, and AA. Prediction error curves, Harrell’s C-statistics, and time-dependent AUCs all showed higher predictive accuracy for MRscore than for FI and AA. These findings were validated in independent samples. Our study demonstrates the ability of the MRscore to strongly enhance survival prediction beyond established markers of biological age, such as FI and AA, and it thus bears potential of a surrogate endpoint for clinical research and intervention.